GlassScriptPhysician profile
Alejandro R Calvo
NPI 1457341760
$463,360.67
in general payments reported to CMS, 2019-2025
37 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $21K · 2021: $54K · 2022: $75K · 2023: $126K · 2024: $90K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $197K · Travel and Lodging: $25K · Consulting Fee: $9,029 · Food and Beverage: $6,254 · Honoraria: $3,213 · Education: $1,813 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $197,334.25 |
| Travel and Lodging | $25,478.96 |
| Consulting Fee | $9,029.00 |
| Food and Beverage | $6,253.74 |
| Honoraria | $3,213.00 |
| Education | $1,813.26 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $173,734.93 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $114,266.08 | 2019-2025 | Tagrisso, Imfinzi |
| Genentech USA, INC. | $59,423.18 | 2019-2023 | Tecentriq |
| Lilly USA, LLC | $55,862.91 | 2022-2024 | Retevmo, Verzenio |
| Mirati Therapeutics, INC. | $21,886.54 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $12,505.87 | 2019-2020 | |
| Daiichi Sankyo INC. | $10,056.29 | 2023 | Enhertu |
| Janssen Biotech, INC. | $2,859.67 | 2025 | Rybrevant, Erleada |
| Astrazeneca Uk Limited | $1,712.50 | 2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,170.00 | 2023 | Rybrevant |
| Gilead Sciences, INC. | $1,011.92 | 2021 | |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $1,000.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $849.30 | 2023-2024 | Opdivo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $727.06 | 2023 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.00 | 2020 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $246.10 | 2020-2025 | |
| Tempus Ai, INC | $202.13 | 2024 | |
| Incyte Corporation | $197.55 | 2021 | |
| Beigene USA, INC. | $187.17 | 2022-2023 | Brukinsa |
| Dova Pharmaceuticals | $186.04 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $179.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $149.29 | 2022-2023 | Imbruvica |
| Intuitive Surgical, INC. | $147.31 | 2025 | |
| Cti Biopharma Corp. | $138.89 | 2022 | |
| Pfizer INC. | $135.96 | 2019-2024 | |
| Glaxosmithkline, LLC. | $123.06 | 2024 | Ojjaara |
| Sobi, INC | $83.99 | 2024 | |
| Astellas Pharma US INC | $81.99 | 2023 | |
| Abbvie INC. | $59.85 | 2024 | |
| Adc Therapeutics America, INC. | $30.23 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Calvo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.